Biggest Manufacturer，Osimertinib AZD-9291 （1421373-66-1） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Osimertinib AZD-9291, CAS#1421373-66-1, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 25KG in stock, pls check:

Name:Osimertinib AZD-9291

CAS#: 1421373-66-1

Chemical Formula: C29H37N7O5S 

Exact Mass: 

Molecular Weight: 595.72 

Elemental Analysis: C, 58.47; H, 6.26; N, 16.46; O, 13.43; S, 5.38

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Osimertinib AZD-9291  Intermediates:

1. Osimertinib AZD-9291 Intermediate:N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine

Cas#1421372-94-2,

We have more than 33kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Osimertinib AZD-9291 Intermediate:N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine

Cas#1421372-67-9,

We have more than43kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3. Osimertinib AZD-9291 Intermediate:N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine

Cas#1421372-66-8

We have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Lung cancer: Diverse EGFR mutations explain AZD9291 resistance. Nat Rev Clin Oncol. 2015 May 19. doi: 10.1038/nrclinonc.2015.97. [Epub ahead of print] PubMed PMID: 25985937.
2: Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4. PubMed PMID: 25939061.
3: Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817. PubMed PMID: 25923549.
4: Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13. PubMed PMID: 25870145.
5: Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Transl Lung Cancer Res. 2014 Dec;3(6):370-2. doi: 10.3978/j.issn.2218-6751.2014.08.02. PubMed PMID: 25806323; PubMed Central PMCID: PMC4367669.
6: Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1. PubMed PMID: 25271963.
7: AZD9291 could be an option for NSCLC. Cancer Discov. 2014 Aug;4(8):OF10. doi: 10.1158/2159-8290.CD-NB2014-077. Epub 2014 May 22. PubMed PMID: 25092747.

8: Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. PubMed PMID: 24893891; PubMed Central PMCID: PMC4315625.

Biggest Manufacturer， Eluxadoline（864821-90-9） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

  2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

 Eluxadoline, CAS#864821-90-9, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 35KG in stock, pls check:

Name:Eluxadoline

CAS#: 864821-90-9

Formula: C32H35N5O5 

Exact Mass: 569.26382 

Molecular Weight: 569.66 

Elemental Analysis:  C, 67.47; H, 6.19; N, 12.29; O, 14.04

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

 Eluxadoline Intermediates:

1. Eluxadoline Intermediate:Eluxadoline Intermediate 1, 

Cas#864825-21-8,

We have more than 45kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Eluxadoline Intermediate:(S)-Methyl 2-Methoxy-5-((1-(4-phenyl-1H-imidazol-2-yl)ethylamino)methyl)benzoate, 

Cas#1391712-57-4,

We have more than 55kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3. Eluxadoline Intermediate:(S)-2-(tert-butoxycarbonylaMino)-3-(4-carbaMoyl-2,6-diMethylphenyl)propanoic acid

Cas#623950-02-7

We have more than 50kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4. Eluxadoline Intermediate:methyl 5-formyl-2-methoxybenzoat

Cas#78515-16-9

We have more than 60kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5. Eluxadoline Intermediate:(S)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine

Cas#864825-23-0

We have more than 55kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Gohil K. Pharmaceutical Approval Update. P T. 2015 Aug;40(8):493-532. PubMed PMID: 26236136; PubMed Central PMCID: PMC4517530.

2: Hornby PJ. Drug discovery approaches to irritable bowel syndrome. Expert Opin Drug Discov. 2015 Aug;10(8):809-24. doi: 10.1517/17460441.2015.1049528. PubMed PMID: 26193876.

3: Garnock-Jones KP. Eluxadoline: First Global Approval. Drugs. 2015 Jul;75(11):1305-10. doi: 10.1007/s40265-015-0436-4. PubMed PMID: 26149369.

4: Traynor K. Eluxadoline approved for irritable bowel syndrome with diarrhea. Am J Health Syst Pharm. 2015 Jul 1;72(13):1078. doi: 10.2146/news150043. PubMed PMID: 26092951.

5: Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14. PubMed PMID: 25491493; PubMed Central PMCID: PMC4402028.

6: Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28. PubMed PMID: 25261794.

7: Andrae DA, Covington PS, Patrick DL. Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome. Clin Ther. 2014 May;36(5):663-79. doi: 10.1016/j.clinthera.2014.04.009. Epub 2014 May 9. PubMed PMID: 24813429.

8: Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013 Dec 13;11:208. doi: 10.1186/1477-7525-11-208. PubMed PMID: 24330412; PubMed Central PMCID: PMC3895767.

9: Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9. PubMed PMID: 23583433.

Biggest Manufacturer， Rucaparib（459868-92-9） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Rucaparib, CAS#459868-92-9, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than58KG in stock, pls check:

Name:Rucaparib

CAS#: 459868-92-9

Formula: C19H18FN3O 

Exact Mass: 323.14339 

Molecular Weight: 323.36 

Elemental Analysis: 

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Rucaparib Intermediates:

1. Rucaparib Intermediate:2-(1,3-dioxoisoindolin-2-yl)acetaldehyde,

Cas#2913-97-5

We have more than 60kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Rucaparib Intermediate:methyl 6-fluoro-1H-indole-4-carboxylate

Cas#1082040-43-4

We have more than 70kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.Rucaparib Intermediate:8-fluoro-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one

Cas#1408282-26-7

We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4.Rucaparib Intermediate:5-bromo-8-fluoro-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one

Cas#283173-80-8

We have more than 64kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5.Rucaparib Intermediate: 3-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-6-fluoro-1H-indole-4-carboxylic acid methyl ester

Cas#1408282-25-6 

We have more than 53kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

6.Rucaparib Intermediate:8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON

Cas#283173-50-2

We have more than 62kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

7.Rucaparib Intermediate:Rucaparib Camsylate

Cas#1859053-21-6

We have more than 57kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

8.Rucaparib Intermediate:5-Fluoro-2-methyl-3-nitrobenzoic acid 

Cas#850462-64-5 

We have more than 56kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

9.Rucaparib Intermediate:5-Fluoro-2-methyl-3-nitrobenzoic acid methyl ester

Cas#697739-03-0 

We have more than 64kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

10.Rucaparib Intermediate:4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldeyde

Cas#283173-84-2 

We have more than 67kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

11.Rucaparib Intermediate:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one hydrochloride

Cas#773059-19-1 

We have more than57kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference:

1: Sun Y, Ding H, Liu X, Li X, Li L. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2014 Jan 14. [Epub ahead of print] PubMed PMID: 24420152.

2: Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013 May;71(5):1191-9. doi: 10.1007/s00280-013-2113-1. Epub 2013 Feb 20. PubMed PMID: 23423489.

3: Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther. 2011 Dec;10(12):2320-9. doi: 10.1158/1535-7163.MCT-11-0356. Epub 2011 Sep 16. PubMed PMID: 21926192; PubMed Central PMCID: PMC3242069.

4: Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23. PubMed PMID: 21183737.

5: Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009 Oct 1;15(19):6106-12. doi: 10.1158/1078-0432.CCR-09-0398. Epub 2009 Sep 29. PubMed PMID: 19789326; PubMed Central PMCID: PMC2756456.

6: Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008 Dec 1;14(23):7917-23. doi: 10.1158/1078-0432.CCR-08-1223. PubMed PMID: 19047122; PubMed Central PMCID: PMC2652879.

Biggest Manufacturer， Omarigliptin（1226781-44-7） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

WEB: www.eosmedchem.com

EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  

TEL: 0086-531-69905422

GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

 Omarigliptin, CAS#1226781-44-7, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than68KG in stock, pls check:

Name:Omarigliptin

CAS#: 1226781-44-7

Formula: C17H20F2N4O3S 

Exact Mass: 398.12242 

Molecular Weight: 398.43 

Elemental Analysis: C, 51.25; H, 5.06; F, 9.54; N, 14.06; O, 12.05; S, 8.05

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Omarigliptin Intermediates:

1.Omarigliptin Intermediate:N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]-Carba, 

cas#951127-25-6,

we have more than 72kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Omarigliptin Intermediate:2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate

cas#1280210-80-1

we have more than 75kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.Omarigliptin Intermediate:2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester

cas#1226781-82-3

we have more than 70kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference:

1: Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks J, Lyons K, He H, Salituro G, Tong S, Patel S, Doss G, Petrov A, Wu J, Xu SS, Sewall C, Zhang X, Zhang B, Thornberry NA, Weber AE. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. doi: 10.1021/jm401992e. Epub 2014 Apr 2. PubMed PMID: 24660890.

2: Biftu T, Qian X, Chen P, Feng D, Scapin G, Gao YD, Cox J, Roy RS, Eiermann G,  He H, Lyons K, Salituro G, Patel S, Petrov A, Xu F, Xu SS, Zhang B, Caldwell C, Wu JK, Lyons K, Weber AE. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected]. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5361-6. doi: 10.1016/j.bmcl.2013.07.061. Epub 2013 Aug 5. Erratum in: Bioorg Med Chem Lett. 2014 Jun 1;24(11):2590. PubMed PMID: 23972441.